Literature DB >> 15101568

Schizophrenia and osteoporosis.

Mike Lean1, Goedele De Smedt.   

Abstract

Although it has been suggested that antipsychotic-induced hyperprolactinaemia in schizophrenic patients may lead to an increased risk of osteoporosis, this has not been proven. Osteoporosis is a multifactorial disease, and untreated patients with schizophrenia are at risk due to both the consequences of the disease and related lifestyle factors. Evidence from available studies does not show that antipsychotic-induced hyperprolactinaemia is an independent risk factor for osteoporosis in schizophrenic patients. Osteoporosis would be expected in women who develop amenorrhoea as a result of hyperprolactinaemia secondary to antipsychotics, but there is no plausible mechanism in men. The uncertainty over this issue underlines the need for full medical and metabolic assessment and monitoring of psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101568     DOI: 10.1097/00004850-200401000-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

1.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

2.  Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2010-02-17       Impact factor: 2.362

Review 3.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.

Authors:  Tae-Young Lee; Moon-Yong Chung; Hae-Kyung Chung; Jin-Hee Choi; Tae-Yong Kim; Hyung-Seok So
Journal:  Psychiatry Investig       Date:  2010-11-30       Impact factor: 2.505

5.  Fundamental Role of Methylenetetrahydrofolate Reductase 677 C → T Genotype and Flavin Compounds in Biochemical Phenotypes for Schizophrenia and Schizoaffective Psychosis.

Authors:  Stephanie Fryar-Williams
Journal:  Front Psychiatry       Date:  2016-11-09       Impact factor: 4.157

6.  Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.

Authors:  Chieh-Hsin Lin; Chun-Yuan Lin; Hong-Song Wang; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

7.  The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.

Authors:  Shih-Pei Shen; Yanfang Liu; Hong Qiu; Kuan-Yi Tsai; Hung-Chi Wu; Wen-Miin Liang; Meng Shu; Frank Huang-Chih Chou
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

Review 8.  Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis.

Authors:  Lucia Gomez; Brendon Stubbs; Ayala Shirazi; Davy Vancampfort; Fiona Gaughran; John Lally
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.